{
event: "article_read",
name: `Odyssey Outcomes Education`,
author: ``,
tags: `Cardiologie | Dyslipidemie`,
publication_date: ``,
interaction_type: "content"
}
Odyssey Outcomes Education
Praluent – Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes - Sub analysis of the Odyssey Outcome Study
.jpg/jcr:content/image%20(81).jpg)
MAT-BE-2200132,1.0,0322-Medtalk_OO Diabetes_EN
Gerelateerde paginas